Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Eli Lilly and Company: Lilly reports full Q4 2024 financial results and provides 2025 guidance Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound.

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

Eli Lilly and Company ( NYSE: LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor ...

While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle ...

Eli Lilly and Company ... Contributing meaningfully to the stock's rise so far this year was the firm’s Q4 2024 earnings report on Feb. 6. Sales of the company’s GLP-1 drugs are still red-hot.

We recently compiled a list of the 30 Best Stocks To Invest In According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising to $1.3bn, with market analysis describing the deal as a “bargain”.